These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 12691208)
1. A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. Doblin R J Psychoactive Drugs; 2002; 34(2):185-94. PubMed ID: 12691208 [TBL] [Abstract][Full Text] [Related]
2. The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder. Amoroso T J Psychoactive Drugs; 2015; 47(5):337-44. PubMed ID: 26579955 [TBL] [Abstract][Full Text] [Related]
3. Progress and promise for the MDMA drug development program. Feduccia AA; Holland J; Mithoefer MC Psychopharmacology (Berl); 2018 Feb; 235(2):561-571. PubMed ID: 29152674 [TBL] [Abstract][Full Text] [Related]
5. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Feduccia AA; Mithoefer MC Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):221-228. PubMed ID: 29524515 [TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Oehen P; Traber R; Widmer V; Schnyder U J Psychopharmacol; 2013 Jan; 27(1):40-52. PubMed ID: 23118021 [TBL] [Abstract][Full Text] [Related]
7. MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics". Sessa B Neurosci Lett; 2017 May; 649():176-180. PubMed ID: 27394687 [TBL] [Abstract][Full Text] [Related]
8. History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). Emerson A; Ponté L; Jerome L; Doblin R J Psychoactive Drugs; 2014; 46(1):27-36. PubMed ID: 24830183 [TBL] [Abstract][Full Text] [Related]
9. Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder. Zeifman RJ; Kettner H; Ross S; Weiss B; Mithoefer MC; Mithoefer AT; Wagner AC Eur J Psychotraumatol; 2024; 15(1):2297536. PubMed ID: 38174611 [TBL] [Abstract][Full Text] [Related]
10. Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA). Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS Am J Ther; 2024 Mar-Apr 01; 31(2):e141-e154. PubMed ID: 38518271 [TBL] [Abstract][Full Text] [Related]
11. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. Marseille E; Mitchell JM; Kahn JG PLoS One; 2022; 17(2):e0263252. PubMed ID: 35213554 [TBL] [Abstract][Full Text] [Related]
12. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Bouso JC; Doblin R; Farré M; Alcázar MA; Gómez-Jarabo G J Psychoactive Drugs; 2008 Sep; 40(3):225-36. PubMed ID: 19004414 [TBL] [Abstract][Full Text] [Related]
13. The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns. Baldo BA Arch Toxicol; 2024 Aug; 98(8):2409-2427. PubMed ID: 38743292 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials. Yang J; Wang N; Luo W; Gao J Psychiatry Res; 2024 Sep; 339():116043. PubMed ID: 38896930 [TBL] [Abstract][Full Text] [Related]
15. Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine-Assisted Therapy for Posttraumatic Stress Disorder: A Review of the Evidence, Neurobiological Plausibility, and Clinical Significance. Price CM; Feduccia AA; DeBonis K J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):464-469. PubMed ID: 36018231 [TBL] [Abstract][Full Text] [Related]
16. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Amoroso T; Workman M J Psychopharmacol; 2016 Jul; 30(7):595-600. PubMed ID: 27118529 [TBL] [Abstract][Full Text] [Related]
17. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. Smith KW; Sicignano DJ; Hernandez AV; White CM J Clin Pharmacol; 2022 Apr; 62(4):463-471. PubMed ID: 34708874 [TBL] [Abstract][Full Text] [Related]
18. Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy. Gully BJ; Eaton E; Capone C; Haass-Koffler CL J Psychopharmacol; 2023 Dec; 37(12):1182-1189. PubMed ID: 38009477 [TBL] [Abstract][Full Text] [Related]
19. Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review. Szafoni S; Więckiewicz G; Pudlo R; Gorczyca P; Piegza M Psychiatr Pol; 2022 Aug; 56(4):823-836. PubMed ID: 37074831 [TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Mithoefer MC; Wagner MT; Mithoefer AT; Jerome L; Doblin R J Psychopharmacol; 2011 Apr; 25(4):439-52. PubMed ID: 20643699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]